KURA logo

Kura Oncology, Inc.


KURA: Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.


Show KURA Financials

Consumer Interest
SEC Filings

Recent trades of KURA by members of U.S. Congress

Recently reported changes by institutional investors

Quarterly net insider trading by KURA's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of KURA in WallStreetBets Daily Discussion


Recent insights relating to KURA

CNBC Recommendations

Recent picks made for KURA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in KURA

Corporate Flights

Flights by private jets registered to KURA